1. |
duced thrombocytopenia in a high-risk cardiac surgical patient. Ann Thorac Surg, 2003, 75 (5):1622-1624.
|
2. |
cardiopulmonary bypass surgery in a patient with heparin-induced thrombocytopenia. J Extra Corpor Technol, 2004, 36:174-177.
|
3. |
aggregation. J Thorac Cardiovasc Surg, 1984, 87 (5):673-677.
|
4. |
Warkentin TE. Clinical presentation of heparin-induced thrombocytopenia. Semin Hematol, 1998, 35 (4 Suppl 5):9-16.
|
5. |
Gurbuz AT, Elliott WG, Zia AA. Heparin-induced thrombocytopenia in the cardiovascular patient:diagnostic and treatment guidelines. Eur J Cardiothorac Surg, 2005, 27 (1):138-149.
|
6. |
Hirsh J, Heddle N, Kelton JG, et al. Treatment of heparin-induced thrombocytopenia:a critical review. Arch Intern Med, 2004, 164:361-369.
|
7. |
Theodore E, Jo-Ann I, Jane C, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia:how much do we need ? J Lab Clin Med, 2005, 146:341-346.
|
8. |
Greinacher A, Warkentin TE. Recognition, treatment, and prevention of heparin-induced thrombocytopenia:review and update. Thromb Res, 2006, 118 (2):165-176.
|
9. |
Denys B, Devreese K. A clinical-laboratory approach contributing to a rapid and reliable diagnosis of heparin-induced thrombocytopenia:An update. Thromb Res, 2009, 124 (5):642-643.
|
10. |
Warkentin TE. New approaches to the diagnosis of heparin-induced thrombocytopenia. Chest, 2005, 127 (2 Suppl):35S-45S.
|
11. |
Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia:recognition, treatment, and prevention:the Seventh ACCP Conference on Antithrombotic and Thrombolytic Therapy. Chest, 2004, 1263 (Suppl):311S-337S.
|
12. |
Warkentin TE, Sheppard JA, Moore JC, et al. Laboratory testing for the antibodies that cause heparin-induced thrombocytopenia:how much class do we need ? J Lab Clin Med, 2005, 146 (6):341-346.
|
13. |
Lo GK, Juhl D, Warkentin TE, et al. Evaluation of pretest clinical score (4Ts)for the diagnosis of heparin-induced thrombocytopenia in two clinical settings. J Thromb Haemost, 2006, 4 (4):759-765.
|
14. |
Aouifi A, Blanc P, Piriou V, et al. Cardiac surgery with cardiopulmonary bypass in patients with type II heparin-induced thrombocytopenia. Ann Thorac Surg, 2001, 71 (2):678-683.
|
15. |
Dyke CM, Smedira NG, Koster A, et al. A comparison of bivalirudin to heparin with protamine eversal in patients undergoing cardiac surgery with ardiopulmonary bypass:The EVOLUTION-ON study. J Thorac Cardiovasc Surg, 2006, 131 (3):533-539.
|
16. |
Crespo EM, Oliveira GB, Honeycutt EF.Evaluation and management of thrombocytopenia and suspected heparin-induced thrombocytopenia in hospitalized patients:The Complications After Thrombocytopenia Caused by Heparin (CATCH) registry. Am Heart J, 2009, 157 (4):651-657.
|
17. |
Koster A, Dyke CM, Aldea G, et al. Bivalirudin during cardiopulmonary bypass in patients with previous or acute heparin-induced thrombocytopenia and heparin antibodies:results of the CHOOSEON trial. Ann Thorac Surg, 2007, 83 (2):572-577.
|
18. |
Bucci C, Geerts WH, Sinclair A, et al. Comparison of the effectiveness and safety of low-molecular weight heparin versus unfractionated heparin anticoagulation after heart valve surgery. Am J Cardiol, 2011, 107 (4):591-594.
|
19. |
Marion D, Marie TL. Heparin-induced thrombocytopenia and cardiopulmonary bypass:anticoagulation with unfractionated heparin and he GPIIb/Ⅲa inhibitor tirofiban and successful use of rFⅦa for post-protamine bleeding due to ersistent platelet blockade. Eur J Cardiothorac Surg, 2008, 34:687-689.
|
20. |
Furukawa K, Ohteki H, Hirahara K, et al. The use of argatroban as an anticoagulant for cardiopulmonary bypass in cardiac operations. J Thorac Cardiovasc Surg, 2001, 122 (6):1255-1256.
|
21. |
Edwards JT, Hambly JK, Worrall NK. Successful use of argatroban as a heparin substitute during cardiopulmonary bypass:Heparin-in.
|
22. |
Meuleman DG, Hobbelen PMJ, Van Dedem G, et al. A novel antithrombotic heparinoid (Org 10172) devoid of bleeding inducing capacity:A survey of pharmacological properties in experimental animal models. Thromb Res, 1982, 27 (3):353-363.
|
23. |
Newman PM, Swansson RL, Chong BH. Heparin-induced thrombocytopenia:IgG binding to PF4-heparin complexes in the fluid phase and cross-reactivity with low-molecular-weight heparin and heparinoid. Thromb Haemost, 1999, 80:292-297.
|
24. |
Grocott HP, Root J, Berkowitz SD, et al. Coagulation complicating cardiopulmonary bypass in a patient with heparin-induced thrombocytopenia receiving the heparinoid, danaparoid sodium. J Cardiothorac Vasc Anesth, 1997, 11 (7):875-877.
|
25. |
Nuttall GA, Oliver WC, Santrach PJ, et al. Patients with a history of type II heparin-induced thrombocytopenia requiring cardiac surgery with cardiopulmonary bypass:A prospective observational case series. Anesth Analg, 2003, 96 (2):344-350.
|
26. |
Despotis GJ, Hogue CW, Saleem R, et al. The relationship between hirudin and activated clotting time:Implications for patients with heparin-induced thrombocytopenia undergoing cardiac surgery.Anesth Analg, 2001, 93 (1):28-32.
|
27. |
Jabr K, Johnson JH, McDonald MH, et al. Plasma-modified ACT can be used to monitor bivalirudin (Angiomax) anticoagulation for on-pump.
|
28. |
Poetzsch B, Madlener K. Management of cardiopulmonary bypass anticoagulation in patients with heparin-induced thrombocytopenia. In Warkentin TE, Greinacher A, Chief editor. Heparin-Induced Thrombocytopenia (ed 3). New York:NY, Marcel Dekker, Inc, 2004. 531-551.
|
29. |
Greinacher A, Eichler P, Lubenow N. Anaphylactic reactions associated with lepirudin in patients with heparin-induced thrombocytopenia (HIT). Circulation, 2003, 108:2062-2065.
|
30. |
Koster A, Chew D, Grundel M. An assessment of different filter systems for extracorporeal elimination of bivalirudin:An in vitro study. Anesth Analg, 2003, 96:1316-1319.
|
31. |
Koster A, Spiess B, Chew DP, et al. Effectiveness of bivalirudin as a replacement for heparin during cardiopulmonary bypass in patients undergoing coronary artery bypass grafting. Am J Cardio, 2004, 93 (3):356-359.
|
32. |
Olinger GN, Hussey CV, Olive JA, et al. Cardiopulmonary bypass for patients with previously documented heparin-induced platelet.
|
33. |
Antoniou T, Kapetanakis E, heodoraki K, et al. Cardiac surgery in patients with heparin-induced thrombocytopenia using preoperatively determined dosages of iloprost. Heart Surg Forum, 2002, 5 (4):354-357.
|
34. |
Koster A, Kukucka M, Bach F, et al. Anticoagulation during cardiopulmonary bypass in patients with heparin-induced thrombocytopenia type II and renal impairment using heparin and the platelet glycoprotein IIb/IIIa antagonist tirofiban. Anesthesiology, 2001, 94:245-251.
|
35. |
Warkentin TE, Greinacher A. Heparin-induced thrombocytopenia and cardiac surgery. Ann Thorac Surg, 2003, 76 (6):2121-2131.
|
36. |
Warkentin TE, Greinacher A, Koster A, et al. Treatment and prevention of heparin-induced thrombocytopenia:American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest, 2008, 133 (6 Suppl):340S-380S.
|